Wnt

The Wnt signaling pathways are a group of signal transduction pathways made of proteins that pass signals from outside of a cell through cell surface receptors to the inside of the cell. Three Wnt signaling pathways have been characterized: the canonical Wnt pathway, the noncanonical planar cell polarity pathway, and the noncanonical Wnt/calcium pathway. All three Wnt signaling pathways are activated by the binding of a Wnt-protein ligand to a Frizzled family receptor, which passes the biological signal to the protein Dishevelled inside the cell. The canonical Wnt pathway leads to regulation of gene transcription, the noncanonical planar cell polarity pathway regulates the cytoskeleton that is responsible for the shape of the cell, and the noncanonical Wnt/calcium pathway regulates calcium inside the cell. The clinical importance of Wnt signaling pathway has been demonstrated by mutations that lead to a variety of diseases, including breast and prostate cancer, glioblastoma, type II diabetes.

ABC99

Cat. No.: HY-122832

ABC99 is an N-hydroxyhydantoin (NHH) carbamate that selectively inhibits the Wnt-deacylating enzyme **NOTUM** (IC_{50}=13 nM). ABC99 preserves Wnt3A signaling in the presence of NOTUM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Adavivint

(SM04690; Lorecivivint)

Cat. No.: HY-109049

Adavivint (SM04690; Lorecivivint) is a potent and selective inhibitor of canonical **Wnt** signaling, with an EC_{50} of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARUK3001185

Cat. No.: HY-147519

ARUK3001185 (Compound 8l) is a potent, selective, orally active and brain-penetrant inhibitor of **Notum** activity with an IC_{50} of 6.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Astragaloside I

(Astrasieversianin IV; Cyclosieversioside B)

Cat. No.: HY-N0432

Astragaloside I, one of the main active ingredients in Astragalus membranaceus, has osteogenic properties. Astragaloside I stimulates osteoblast differentiation through the **Wnt/β-catenin** signaling pathway.
.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BML-284

Cat. No.: HY-19987

BML-284 is a potent and cell-permeable **Wnt** signaling activator. BML-284 induces TCF-dependent transcriptional activity with an EC_{50} of 700 nM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

BML-284 hydrochloride

Cat. No.: HY-19987A

BML-284 hydrochloride is a potent and cell-permeable **Wnt** signaling activator. BML-284 induces TCF-dependent transcriptional activity with an EC_{50} of 700 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Carboxylesterase-IN-2

Cat. No.: HY-142688

Carboxylesterase-IN-2 (compound 4u) is a potent inhibitor of **Carboxylesterase Notum** with an IC_{50} less than or equal to 10 nM. Notum is a negative regulator of Wnt signaling acting through the hydrolysis of a palmitoleoylate ester, which is required for Wnt activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Carboxylesterase-IN-3

Cat. No.: HY-142689

Carboxylesterase-IN-3 (compound 4y) is a potent inhibitor of **Carboxylesterase Notum** with an IC_{50} less than or equal to 10 nM. Notum is a negative regulator of Wnt signaling acting through the hydrolysis of a palmitoleoylate ester, which is required for Wnt activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cardiogenol C

Cat. No.: HY-12319

Cardiogenol C is a potent cell-permeable pyrimidine inducer which prompts the **differentiation of ESCs into cardiomyocytes** (EC_{50}=100 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cardiogenol C hydrochloride

Cat. No.: HY-12319A

Cardiogenol C hydrochloride is a potent cell-permeable pyrimidine inducer which prompts the **differentiation of ESCs into cardiomyocytes** (EC_{50}=100 nM).



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCT251545

Cat. No.: HY-12681

CCT251545 is an orally bioavailable and potent inhibitor of **WNT** signaling with an IC_{50} of 5 nM in 7dF3 cells. CCT251545 is a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Coronaridine

Cat. No.: HY-121118

Coronaridine, an iboga type alkaloid, inhibits the **wnt signaling** pathway by decreasing β-catenin expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

CWP232228

Cat. No.: HY-18959

CWP232228, a highly potent selective **Wnt/β-catenin** signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

DK419

Cat. No.: HY-112799

DK419 is a potent and orally active **Wnt/β-catenin** signaling inhibitor, with an IC_{50} of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Echinacoside

Cat. No.: HY-N0020

Echinacoside, one of the phenylethanoids isolated from the stems of Cistanche salsa, effectively inhibits **Wnt/β-catenin signaling**. Echinacoside elicits neuroprotection by activating Trk receptors and their downstream signal pathways. Antiosteoporotic activity.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

EMT inhibitor-1

Cat. No.: HY-101275

EMT inhibitor-1 is an inhibitor of of **Hippo**, **TGF-β**, and **Wnt** signaling pathways with antitumor activities.



Purity: 99.27%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

ETC-159

(ETC-1922159)

Cat. No.: HY-18988

ETC-159 (ETC-1922159) is a potent, orally available **PORCN** inhibitor. ETC-159 inhibits β-catenin reporter activity with an IC_{50} of 2.9 nM.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

exo-IWR-1

Cat. No.: HY-108437

exo-IWR-1, an inactive stereoisomer of Endo-IWR-1, is a negative control of IWR-1 (HY-12238). IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FH535

Cat. No.: HY-15721

FH535 is an inhibitor of **Wnt/β-catenin** and **PPAR**, with anti-tumor activities.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

FIDAS-3

Cat. No.: HY-136145

FIDAS-3 is a stilbene derivative and is a potent **Wnt** inhibitor with an IC_{50} of 4.9 μM for **methionine S-adenosyltransferase 2A (MAT2A)**. FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for **MAT2A** binding. FIDAS-3 has anticancer activities.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Foxy-5

Cat. No.: HY-P1416

Foxy-5, a **WNT5A** agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Foxy-5 TFA

Cat. No.: HY-P1416A

Foxy-5 TFA, a **WNT5A** agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells.



Purity: 99.10%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Fz7-21

(Ac-LPSDDLEFWCHVMY-NH2)

Cat. No.: HY-P1454

Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2), a peptide antagonist of **Frizzled 7 (FZD 7)** receptors, selectively binds to FZD7 CRD subclass. The **EC_{50}** values are 58 and 34 nM for human and mouse FZD7 CRD, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fz7-21 TFA

(Ac-LPSDDLEFWCHVMY-NH2 TFA)

Cat. No.: HY-P1454A

Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA , a peptide antagonist of **Frizzled 7 (FZD 7)** receptors, selectively binds to FZD7 CRD subclass. The **EC_{50}** values are 58 and 34 nM for human and mouse FZD7 CRD, respectively.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

FzM1

Cat. No.: HY-116553

FzM1 is a negative allosteric modulator (NAM) of **Frizzled receptor FZD4**. FzM1 reduces WNT5A-dependent WNT responsive element (WRE) activity (log EC_{50inh} = −6.2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FzM1.8

Cat. No.: HY-117163

FzM1.8 derives from FzM1, is an allosteric agonist of **FZD4** with **pEC_{50}** of 6.4. FzM1.8 binds to FZD4 and activates the **WNT/β-catenin** pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand.



Purity: 98.20%
Clinical Data:
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Gallocyanine chloride

Cat. No.: HY-D0961

Gallocyanine chloride, a synthetic blue dyestuff, blocks **DKK1** inhibitory activity by disrupting **DKK1/LRP6** interaction. Its association with LRP6 is weak (IC_{50} of about 3 μM in the inhibition of DKK1 binding).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gigantol

Cat. No.: HY-N2523

Gigantol is a bibenzyl compound derived from several medicinal orchids. Giganto shows promising therapeutic potential against cancer cells. Gigantol is a novel inhibitor of the **Wnt/β-catenin** pathway.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ginkgetin

Cat. No.: HY-N0889

Ginkgetin, a biflavone, is isolated from Ginkgo biloba leaves. Ginkgetin exhibit anti-tumor, anti-inflammatory, neuroprotective, anti-fungal activities. Ginkgetin is also a potent inhibitor of **Wnt signaling**, with an **IC_{50}** of 5.92 μM.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Hematein

Cat. No.: HY-119751

Hematein is a oxidation product of hematoxylin acted as a dye. Hematein is an allosteric **casein kinase II** inhibitor with an **IC_{50}** of 0.74 μM. Hematein inhibits **Akt/PKB Ser129** phosphorylation, the **Wnt/TCF** pathway and increases **apoptosis** in lung cancer cells.



Purity: 74.90%
Clinical Data:
Size: 10 mM × 1 mL, 500 mg, 1 g

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Heparan Sulfate

Cat. No.: HY-101916

Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HLY78

Cat. No.: HY-122816

HLY78 is an activator of the **Wnt/β-catenin** signaling pathway, which targets the DIX domain of Axin and potentiates the Axin-LRP6 association to promote Wnt signaling transduction.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

iCRT 14

Cat. No.: HY-16665

iCRT 14 is a novel potent inhibitor of **β-catenin-responsive transcription (CRT)**, with IC_{50} of 40.3 nM against Wnt responsive STF16 luciferase.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

iCRT3

Cat. No.: HY-103705

iCRT3 is an inhibitor of both **Wnt** and **β-catenin-responsive transcription**.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ipivivint

Cat. No.: HY-137443

Ipivivint (compound 38) is a potent **CDC-like kinase (CLK)** inhibitor with EC_{50}s of 1 nM, 7 nM for CLK2 and CLK3, respectively. Ipivivint inhibits **Wnt** pathway (EC_{50}=13 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IQ 1

Cat. No.: HY-10593

IQ 1 has many functions such as decreasing Wnt-stimulated phosphorylation, maintaining the pluripotency of murine ESCs, preventing PP2A/Nkd interaction and so on. IQ 1 maintains the pluripotency of murine ESCs in long-term culture in a Wnt-dependent manner.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

IWP-2

Cat. No.: HY-13912

IWP-2 is an inhibitor of **Wnt** processing and secretion with an IC_{50} of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IWP-3

Cat. No.: HY-100536

IWP-3 is an potent inhibitor of **Wnt** production with an IC_{50} of 40 nM. IWP-3 inhibits Porcupine (Porcn) function thereby blocking palmitoylation of Wnt proteins. IWP-3 inhibits CK1γ3 and CK1ε only moderately and does not inhibit CK1α.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IWP-4

Cat. No.: HY-12879

IWP-4 is a small molecule **Wnt** inhibitor with an IC_{50} of 25 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IWP-O1

Cat. No.: HY-100853

IWP-O1 is a highly potent **Porcupine (Porcn)** inhibitor, with an EC_{50} of 80 pM in L-Wnt-STF cells. IWP-O1 prevents the secretion of **Wnt** proteins. IWP-O1 suppresses the phosphorylation of Dvl2/3 and LRP6 in HeLa cells.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IWR-1

(endo-IWR 1; IWR-1-endo)

Cat. No.: HY-12238

IWR-1 is a **tankyrase** inhibitor which inhibits Wnt/β-catenin signaling pathway.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JW67

Cat. No.: HY-108442

JW67 inhibits the canonical **Wnt** signaling with an IC_{50} of 1.17μM. JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of **Wnt** target genes.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JW74

Cat. No.: HY-19739

JW74 antagonizes LiCl-induced activation of the canonical **Wnt** signaling with an IC_{50} of 420 nM.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KY-02327

Cat. No.: HY-124156

KY-02327, a metabolically stabilized KY-02061 analog, is a potent **Dishevelled (Dvl)-CXXC5** interaction inhibitor. KY-02327 shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KY-02327 acetate

Cat. No.: HY-124156A

KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent **Dishevelled (Dvl)-CXXC5** interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KY-05009

Cat. No.: HY-124745

KY-05009 is an ATP-competitive **Traf2- and Nck-interacting kinase (TNIK)** inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 25 mg, 100 mg

KY02111

Cat. No.: HY-13815

KY02111 is a canonical **WNT signaling (β-catenin)** inhibitor which promotes differentiation of hPSCs to cardiomyocytes. KY02111 can be used for the research of human cardiomyocyte regeneration.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

KY1220

Cat. No.: HY-102028

KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the **Wnt/β-catenin** pathway; with an IC_{50} of 2.1 μM in HEK293 reporter cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KY19382

(A3051)

Cat. No.: HY-131447

KY19382 is a potent and orally active dual inhibitor of **CXXC5-DVL** and **GSK3β**, with IC_{50}s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KYA1797K

Cat. No.: HY-101090

KYA1797K is a potent and selective **Wnt/β-catenin** inhibitor with an IC_{50} of 0.75 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-Quebrachitol

Cat. No.: HY-N2375

L-Quebrachitol is a natural product isolated from many plants, promotes osteoblastogenesis by upregulation of **BMP-2**, runt-related transcription factor-2 (**Runx2**), **MAPK** (ERK, JNK, p38α), and **Wnt/β-catenin** signaling pathway.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Laduviglusib

(CHIR-99021; CT99021)

Cat. No.: HY-10182

Laduviglusib (CHIR-99021) is a potent and selective **GSK-3α/β** inhibitor with IC_{50}s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for **GSK-3** over CDC2, ERK2 and other protein kinases.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Laduviglusib monohydrochloride

(CHIR-99021 monohydrochloride; CT99021 monohydrochloride)

Cat. No.: HY-10182A

Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective **GSK-3α/β** inhibitor with IC_{50}s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for **GSK-3** over CDC2, ERK2 and other protein kinases.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Laduviglusib trihydrochloride

(CHIR-99021 trihydrochloride; CT99021 trihydrochloride)

Cat. No.: HY-10182B

Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective **GSK-3α/β** inhibitor with IC_{50}s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for **GSK-3** over CDC2, ERK2 and other protein kinases.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LP-922056

Cat. No.: HY-131034

LP-922056 is an orally active, highly potent **Notum Pectinacetylesterase** inhibitor with EC_{50}s of 21 nM, 55 nM in human and mouse cellular assay, respectively. LP-922056 significantly increases midshaft femur cortical bone thickness in mice and rats.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Methyl vanillate

Cat. No.: HY-75342

Methyl vanillate, one of the ingredients in Hovenia dulcis Thunb, is a **Wnt/β-catenin** pathway activator. A benzoate ester that is the methyl ester of vanillic acid. It has a role as an antioxidant and a plant metabolite.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

MSAB

Cat. No.: HY-120697

MSAB is a potent and selective inhibitor of **Wnt/β-catenin** signaling. MSAB binds to β-catenin promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide

Cat. No.: HY-N7702

N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

NCB-0846

Cat. No.: HY-100830

NCB-0846 is an orally available **TNIK** inhibitor with an IC_{50} of 21nM.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Neurodazine

Cat. No.: HY-108439

Neurodazine is an imidazole-based small molecule, serve as a promoter of **neurogenesisin pluripotent cells**. Neurodazine promotes neurogenesis by activating **Wnt** and **Shh** signaling pathways. Neurodazine selectively suppresses astrocyte differentiation of P19 cells.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

NLS-StAx-h

Cat. No.: HY-P2272

NLS-StAx-h is a selective, stapled peptide inhibitor of **Wnt** signaling with an IC_{50} of 1.4 μM. NLS-StAx-h efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h inhibits proliferation and migration of colorectal cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg

Pamidronic acid

Cat. No.: HY-B0012

Pamidronic acid is a drug used to treat a broad spectrum of bone absorption diseases.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

PNU-74654

Cat. No.: HY-101130

PNU-74654 is an inhibitor of **Wnt/β-catenin** pathway with an IC_{50} of 129.8 μM in NCI-H295 cell.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Prinaberel

(ERB-041)

Cat. No.: HY-14933

Prinaberel (ERB-041) is a potent and selective **estrogen receptor (ER) β** agonist with IC_{50}s of 5.4, 3.1 and 3.7 nM for human, rat and mouse ERβ, respectively. Prinaberel displays >200-fold selectivity for ERβ over ERα.



Purity: 98.62%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg

Prodigiosin

(Prodigiosine)

Cat. No.: HY-100711

Prodigiosin (Prodigiosine) is a red pigment produced by bacteria as a bioactive secondary metabolite. Prodigiosin is a potent inhibitor of the **Wnt/β-catenin** pathway.



Purity: 95.44%
Clinical Data: No Development Reported
Size: 100 μg

Prodigiosin hydrochloride

(Prodigiosine hydrochloride)

Cat. No.: HY-100711A

Prodigiosin (Prodigiosine) hydrochloride is a red pigment produced by bacteria as a bioactive secondary metabolite. Prodigiosin hydrochloride is a potent proapoptotic agent, and inhibits **Wnt/β-catenin** pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg, 250 μg, 1 mg

Pyrvinium pamoate

(Pyrvinium embonate)

Cat. No.: HY-A0293

Pyrvinium pamoate is an FDA-approved antihelmintic drug that inhibits **WNT** pathway signaling.



Purity: 98.72%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Salinomycin

(Procoxacin)

Cat. No.: HY-15597

Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, selectively inhibits the growth of **gram-positive bacteria**. Salinomycin is a potent inhibitor of **Wnt/β-catenin** signaling, blocks Wnt-induced LRP6 phosphorylation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Salinomycin sodium salt

(Salinomycin sodium; Sodium salinomycin)

Cat. No.: HY-17439

Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of **Wnt/β-catenin** signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

SKI II

Cat. No.: HY-13822

SKI-II is an oral active and synthetic inhibitor of **sphingosine kinase (SK)** activity, with IC_{50} values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

SKL2001

Cat. No.: HY-101085

SKL2001 is an agonist of the **Wnt/β-catenin** pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Specnuezhenide

((8E)-Nuezhenide)

Cat. No.: HY-N0665

Specnuezhenide ((8E)-Nuezhenide) is isolated from the fruits of Ligustrum lucidum. Specnuezhenide ((8E)-Nuezhenide) can inhibit IL-1β-induced inflammation in chondrocytes via inhibition of **NF-κB** and **wnt/β-catenin** signaling.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SSTC3

Cat. No.: HY-120675

SSTC3 is a **casein kinase 1α (CK1α)** activator (K_d = 32 nM) that inhibits **WNT** signaling (EC_{50} = 30 nM). SSTC3 exhibits minimal gastrointestinal toxicity compared to other classes of WNT inhibitors.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Teplinovivint

Cat. No.: HY-137454

Teplinovivint is a potent **wnt/β-catenin** signaling pathway inhibitor. Teplinovivint has anti-inflammatory activity and has the potential for tendinopathy research.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TNIK-IN-5

Cat. No.: HY-143437

TNIK-IN-5 is an efficient **TNIK** inhibitor with IC_{50} of 0.05 μM. TNIK-IN-5 efficiently inhibits **Wnt** signaling in intact cells. TNIK-IN-5 shows excellent in vitro anti-colorectal cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Triptonide

(NSC 165677; PG 492)

Cat. No.: HY-32736

Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a **Wnt** signaling inhibitor with an IC_{50} of appropriately 0.3nM.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg

UU-T02

Cat. No.: HY-117233

UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction **(β-catenin/Tcf PPI)** with a K_i of 1.36 μM. UU-T02 inhibits canonical **Wnt** signaling and the growth of colorectal cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Withanolide B

Cat. No.: HY-129566

Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via **ERK1/2** and **Wnt/β-catenin signaling pathways**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Wnt pathway activator 1

Cat. No.: HY-135516

Wnt pathway activator 1 is a potent **Wnt** activator extracted from patent WO2012024404A1, compound 1, has an EC_{50}s of 28-29 nM.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Wnt pathway activator 2

Cat. No.: HY-136073

Wnt pathway activator 2 is a potent **Wnt** activator extracted from patent WO2012024404A1, compound 2, has an EC_{50}s of 13 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Wnt-C59

(C59)

Cat. No.: HY-15659

Wnt-C59 (C59) is a highly potent and oral **porcupine (PORCN)** inhibitor with an IC_{50} of 74 pM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Wnt/β-catenin agonist 1

Cat. No.: HY-114321

Wnt/β-catenin agonist 1 (compound 3f) is a **Wnt/β-catenin** signalling pathway agonist, with an EC_{50} of 0.27 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Wogonin

Cat. No.: HY-N0400

Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of **CDK8** and **Wnt**, and exhibits anti-inflammatory and anti-tumor effects.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

YB-0158

(Wnt pathway inhibitor 2)

Cat. No.: HY-136541

YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent **colorectal cancer stem cell (CSC)** targeting agent. YB-0158 disrupts Sam68-Src interactions and induces **apoptosis** in CRC cells. Anti-cancer activities.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

β-catenin-IN-3

Cat. No.: HY-147007

β-catenin-IN-3 (compound C2) is a potent and selective **β-catenin** inhibitor with a K_D value of 54.96 nM. β-catenin-IN-3 acts by targeting a cryptic allosteric modulation site of β-catenin. β-catenin-IN-3 can significantly reduce viability of β-catenin-driven cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg